Navigation Links
3SBio Inc. to Hold Annual General Meeting

SHENYANG, China, Aug. 20 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that the 2008 Annual General Meeting of Shareholders of 3SBio Inc. will be held on September 12, 2008 (Friday) at 10:00 a.m. (Beijing time) at No.3 A1, Road 10, Shenyang Economy & Technology Development Zone, Shenyang 110027, People's Republic of China.

Further information is available on the 3SBio Inc. website at under the heading "Investors", and additional information about 3SBio Inc. is available in its annual report on Form 20-F for the year ending December 31, 2007 filed with the U.S. Securities and Exchange Commission, which can be accessed at the following link: .

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China.

For more information, please visit 3SBio on the web at .

For further information, please contact:

Investor Contact:

Kevin Teo, CFO

3SBio Inc.

Tel: +86-24-2581-1820

Investor Relations (US):

Mahmoud Siddig

Taylor Rafferty

Tel: +1-212-889-4350

Investor Relations (HK):

Ruby Yim

Taylor Rafferty

Tel: +852-3196-3712

Media Contact:

Jason Marshall

Taylor Rafferty

Tel: +1-212-889-4350

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. Announces Second Quarter 2008 Results
2. 3SBio Inc. Schedules 2008 Second Quarter Earnings Release On Tuesday, August 12, 2008
3. 3SBio Inc. to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
4. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
5. 3SBio Inc. to Present at The Oppenheimer 2nd Annual China Dragon Call Conference
6. 3SBio Inc. Announces First Quarter 2008 Results
7. 3SBio Inc. Schedules 2008 First Quarter Earnings Release on Wednesday, May 14, 2008
8. 3SBio Inc. Approves Share Repurchase Program
9. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
10. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
11. 3SBio Inc. Announces Change to the Board of Directors
Post Your Comments:
(Date:11/25/2015)... BRUSSELS , November 25, 2015 ... la première fois les différences entre les souches ... de celles des êtres humains . Ces ... comprendre et envisager la prise en charge efficace de ... ent diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... and HOLLISTON, Mass. , ... Inc. (Nasdaq: HART ), a biotechnology company developing ... CEO Jim McGorry will present at the ... 1, 2015 at 2:30 p.m. PT. The presentation will ... for 30 days. Management will also be available at ...
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015 ... that management will participate in a fireside chat discussion ... New York . The discussion is ... Time. .  A replay will ... Contact:  Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate ...
Breaking Biology Technology:
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):